DCF — PROV REGL MED CENTER EVERETT
Enterprise Value: $-2.4B
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-2.4B
Enterprise Value
$-741.4M
PV of Cash Flows
$-1.7B
PV of Terminal Value
$-2.7B
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $850.3M | $-162.5M | -19.0% | $-198.5M | $-180.4M |
| Year 2 | $875.8M | $-158.6M | -18.0% | $-195.7M | $-161.7M |
| Year 3 | $902.0M | $-154.3M | -17.0% | $-192.5M | $-144.6M |
| Year 4 | $929.1M | $-154.3M | -17.0% | $-193.6M | $-132.3M |
| Year 5 | $957.0M | $-156.5M | -16.0% | $-197.1M | $-122.4M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-2.4B. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$825.5M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.1960829682843933
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5